Advertisement

Topics

ORIDIS Biomed GmbH Company Profile

17:38 EST 15th December 2018 | BioPortfolio

ORIDIS™ Biomed is a biomedical company focusing on the discovery and development of therapeutics and targeted treatment solutions for liver cancer and metabolic diseases of the liver.ORIDIS™ Biomed has built a potent drug discovery and development organization based on its extensive scientific and clinical expertise in the area of liver disease, its proprietary TISSOMICS™ research engine, and a seasoned management team with broad experience in industrial drug discovery and commercial product development. Since its inception, the Company has identified multiple compounds and lead series, resulting in a diversified portfolio of research and development programs.
ORIDIS™ Biomed’s most advanced program for the treatment of primary liver cancer (hepato-cellular cancer, HCC) has identified three compound series. Selection of a clinical candidate is currently ongoing.
Other R&D programs include the optimization and development of compounds for the treatment of oxidative stress involved in metabolic liver diseases, such as non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH).
Since 2001, the Company has proven its ability to consistently feed its research pipeline with compounds and lead series identified by its TISSOMICS™ research engine.
In addition to its strong R&D pipeline, ORIDIS™ Biomed is actively evaluating in-licensing opportunities in the area of liver disease.

Location

Stiftingtalstrasse 3-5
Graz
A-8010
Germany

Contact

Phone: 43-316-325776
Fax: 43-316-325776 22
Email: info@oridis-biomed.com


News Articles [293 Associated News Articles listed on BioPortfolio]

Q BioMed Acquires Cancer Pain Drug From GE Healthcare

NewsThe acquisition of Metastron gives Q BioMed ownership of the drug and related market authorizations in 22 countries.Contributed Author: 

Q BioMed and SRI Collaborate on Formulation and Preclinical Work on Autism

NewsThe collaborative agreement will include early clinical manufacturing of QBM-001 in support of Q BioMed's Autistic Spectrum Disorder drug development program.

Harbour BioMed gets rights to Glenmark's bispecific antibody

Glenmark Pharmaceuticals SA granted Harbour BioMed exclusive rights to develop and sell its bispecific antibody GBR1302 for solid tumors in Greater China. Harbour BioMed also retains a manufacturing o...

Harbour BioMed raises $85m to accelerate growth of therapeutic pipeline

Harbour BioMed is engaged in the discovery and development of therapeutics for oncology and immunological diseases. The financing round was led by GIC Private Limited, and participants included The p...

Q BioMed takes final step to gaining FDA approval to manufacture its spearhead drug

Q BioMed Inc (OTCQB: QBIO) CEO Denis Corin tells Proactive Investors the commercial-stage biotech is taking the final step in the approval process of its bone pain relief treatment, the "spearhead'"...

Orchestra BioMed secures $41m funding for cardiovascular product candidates

Orchestra BioMed will use the funding to support continued late-stage clinical development of its Virtue sirolimus-eluting balloon (SEB) to treat artery disease and BackBeat cardiac neuromodulation th...

Q BioMed’s Metastron acquisition ‘positive development,’ advances pipeline, says Brookline Capital Markets

Analyst Kumaraguru Raja says Q BioMed’s ownership of this non-opioid cancer pain drug will give it ‘immediate, established, and long-term revenue’

Deals this week: Harbour BioMed, Emergent BioSolutions, Sierra Oncology

Harbour BioMed has signed a collaboration agreement with Kelun-Biotech Biopharmaceutical to develop and commercialise A167, an anti-PD-L1 antibody indicated for...Read More... The post Deals this week...

PubMed Articles [34 Associated PubMed Articles listed on BioPortfolio]

A comparison of different farrowing systems - Part 1: Effects on the activity of the sow.

The aim of this study was to determine whether a 3-axis accelerometer (MSR 145B V5.106, MSR Electronics GmbH, Seuzach, Switzerland) can continuously record and display the activity behaviour of sows o...

Comment on "Using Innovative Acoustic Analysis to Predict the Postoperative Outcomes of Unilateral Vocal Fold Paralysis".

Corrigendum to "Carnitine/organic cation transporter 2 (OCTN2) contributes to rat epididymal epithelial cell growth and proliferation" Biomed. Pharmacother. 93(2017):444-450.

A purpose-designed monofilament-fibre pad for debridement of hard-to-reach wounds: experience in clinical practice.

Effective and comfortable debridement is an important part of managing complex wounds. This user test evaluated a monofilament-fibre pad (with handle) (Debrisoft Lolly, Lohmann & Rauscher GmbH & Co. K...

Field study on loose farrowing in cold barns.

The aim of this field study was to examine the loose farrowing system in view of practicability, particularly to monitor piglet losses and their causes, on a farm proceeding in accordance with the BIO...

Clinical Trials [56 Associated Clinical Trials listed on BioPortfolio]

Amendment of rTSST-1 Variant Vaccine Phase 1 First-in-man Trail

Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen to...

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

XC8 in the Treatment of Patients With Bronchial Asthma

A multicenter, double-blind, randomized, parallel-group comparative Phase II clinical study to assess the efficacy and safety of different doses of XC8 vs Placebo in patients with partly c...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Reproducibility of Malaria Challenge in Healthy Volunteers

This is a prospective, single arm, single intervention safety and immunogenicity study in 6 healthy, malaria-naive adults, conducted to demonstrate the successful implementation of the wel...

Companies [579 Associated Companies listed on BioPortfolio]

ORIDIS Biomed GmbH

ORIDIS™ Biomed is a biomedical company focusing on the discovery and development of therapeutics and targeted treatment solutions for liver cancer and metabolic diseases of the liver.ORIDIS™ Biome...

Biomed Pharmaceuticals

The Company is a leading pharmacy provider of intravenous and injectable medications for patients with chronic disorders. Biomed treats a variety of immune deficient and autoimmun...

BioMed Central Ltd

BioMed Central is an independent publishing house committed to providing immediate open access to peer-reviewed biomedical researchAll original research articles published by BioMed Central are made f...

Biomed

Biomed AG wurde 1951 in Zürich gegründet und hat sich seither als Handelsunternehmen für pharmazeutische Produkte im Schweizer Markt etabliert. Biomed ist spezialisiert auf den Handel mit rezeptpfl...

Alpine Biomed Corporation

Alpine Biomed is a global leader in specialty diagnostic devices for the gastroenterology and neurology clinical markets. The company produces diagnostic tools used for gastroesophageal reflux diseas...

More Information about "ORIDIS Biomed GmbH" on BioPortfolio

We have published hundreds of ORIDIS Biomed GmbH news stories on BioPortfolio along with dozens of ORIDIS Biomed GmbH Clinical Trials and PubMed Articles about ORIDIS Biomed GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ORIDIS Biomed GmbH Companies in our database. You can also find out about relevant ORIDIS Biomed GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Corporate Database Quicklinks



Searches Linking to this Company Record